Early ovarian cancer

A review of ITS genetic and biologic factors, detection, and treatment

Matthew P. Boente, Andrew K. Godwin, Matthew F. Kohler, Kenneth Buetow, Thomas C. Hamilton, Kenneth Buetow, W. Michael Hogan, Robert C. Young

Research output: Contribution to journalArticle

Abstract

Early-stage ovarian carcinoma requires comprehensive surgical staging; reexploration for patients who had suboptimal initial surgery would indicate an apparent early ovarian carcinoma. After proper surgery, patients can be subdivided into a high- or low-risk group, and treatment options then can be discussed with the patient. Patients in the low-risk category can be followed up expectantly without any form of adjuvant therapy. Patients in the high-risk category, however, should be encouraged to participate in randomized clinical trials, because it is unclear at the current time which combination of chemotherapy and how many treatments should be used. A platinum-based paclitaxel regimen probably should be used, although the relative merits of carboplatin and cisplatin and the appropriate schedule for taxol (1 hour vs. 3 hours vs. 24 hours vs. 96 hours) are yet unknown. It is hoped that clinicians will continue to encourage patients to participate in randomized clinical trials so that optimal therapy for early ovarian cancer can be established.

Original languageEnglish (US)
Pages (from-to)86-137
Number of pages52
JournalCurrent Problems in Cancer
Volume20
Issue number2
StatePublished - 1996
Externally publishedYes

Fingerprint

Biological Factors
Ovarian Neoplasms
Paclitaxel
Therapeutics
Randomized Controlled Trials
Carcinoma
Carboplatin
Combination Drug Therapy
Platinum
Cisplatin
Appointments and Schedules

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Boente, M. P., Godwin, A. K., Kohler, M. F., Buetow, K., Hamilton, T. C., Buetow, K., ... Young, R. C. (1996). Early ovarian cancer: A review of ITS genetic and biologic factors, detection, and treatment. Current Problems in Cancer, 20(2), 86-137.

Early ovarian cancer : A review of ITS genetic and biologic factors, detection, and treatment. / Boente, Matthew P.; Godwin, Andrew K.; Kohler, Matthew F.; Buetow, Kenneth; Hamilton, Thomas C.; Buetow, Kenneth; Michael Hogan, W.; Young, Robert C.

In: Current Problems in Cancer, Vol. 20, No. 2, 1996, p. 86-137.

Research output: Contribution to journalArticle

Boente, MP, Godwin, AK, Kohler, MF, Buetow, K, Hamilton, TC, Buetow, K, Michael Hogan, W & Young, RC 1996, 'Early ovarian cancer: A review of ITS genetic and biologic factors, detection, and treatment', Current Problems in Cancer, vol. 20, no. 2, pp. 86-137.
Boente, Matthew P. ; Godwin, Andrew K. ; Kohler, Matthew F. ; Buetow, Kenneth ; Hamilton, Thomas C. ; Buetow, Kenneth ; Michael Hogan, W. ; Young, Robert C. / Early ovarian cancer : A review of ITS genetic and biologic factors, detection, and treatment. In: Current Problems in Cancer. 1996 ; Vol. 20, No. 2. pp. 86-137.
@article{9fd662c31dda442ba12a62cd04be38f7,
title = "Early ovarian cancer: A review of ITS genetic and biologic factors, detection, and treatment",
abstract = "Early-stage ovarian carcinoma requires comprehensive surgical staging; reexploration for patients who had suboptimal initial surgery would indicate an apparent early ovarian carcinoma. After proper surgery, patients can be subdivided into a high- or low-risk group, and treatment options then can be discussed with the patient. Patients in the low-risk category can be followed up expectantly without any form of adjuvant therapy. Patients in the high-risk category, however, should be encouraged to participate in randomized clinical trials, because it is unclear at the current time which combination of chemotherapy and how many treatments should be used. A platinum-based paclitaxel regimen probably should be used, although the relative merits of carboplatin and cisplatin and the appropriate schedule for taxol (1 hour vs. 3 hours vs. 24 hours vs. 96 hours) are yet unknown. It is hoped that clinicians will continue to encourage patients to participate in randomized clinical trials so that optimal therapy for early ovarian cancer can be established.",
author = "Boente, {Matthew P.} and Godwin, {Andrew K.} and Kohler, {Matthew F.} and Kenneth Buetow and Hamilton, {Thomas C.} and Kenneth Buetow and {Michael Hogan}, W. and Young, {Robert C.}",
year = "1996",
language = "English (US)",
volume = "20",
pages = "86--137",
journal = "Current Problems in Cancer",
issn = "0147-0272",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Early ovarian cancer

T2 - A review of ITS genetic and biologic factors, detection, and treatment

AU - Boente, Matthew P.

AU - Godwin, Andrew K.

AU - Kohler, Matthew F.

AU - Buetow, Kenneth

AU - Hamilton, Thomas C.

AU - Buetow, Kenneth

AU - Michael Hogan, W.

AU - Young, Robert C.

PY - 1996

Y1 - 1996

N2 - Early-stage ovarian carcinoma requires comprehensive surgical staging; reexploration for patients who had suboptimal initial surgery would indicate an apparent early ovarian carcinoma. After proper surgery, patients can be subdivided into a high- or low-risk group, and treatment options then can be discussed with the patient. Patients in the low-risk category can be followed up expectantly without any form of adjuvant therapy. Patients in the high-risk category, however, should be encouraged to participate in randomized clinical trials, because it is unclear at the current time which combination of chemotherapy and how many treatments should be used. A platinum-based paclitaxel regimen probably should be used, although the relative merits of carboplatin and cisplatin and the appropriate schedule for taxol (1 hour vs. 3 hours vs. 24 hours vs. 96 hours) are yet unknown. It is hoped that clinicians will continue to encourage patients to participate in randomized clinical trials so that optimal therapy for early ovarian cancer can be established.

AB - Early-stage ovarian carcinoma requires comprehensive surgical staging; reexploration for patients who had suboptimal initial surgery would indicate an apparent early ovarian carcinoma. After proper surgery, patients can be subdivided into a high- or low-risk group, and treatment options then can be discussed with the patient. Patients in the low-risk category can be followed up expectantly without any form of adjuvant therapy. Patients in the high-risk category, however, should be encouraged to participate in randomized clinical trials, because it is unclear at the current time which combination of chemotherapy and how many treatments should be used. A platinum-based paclitaxel regimen probably should be used, although the relative merits of carboplatin and cisplatin and the appropriate schedule for taxol (1 hour vs. 3 hours vs. 24 hours vs. 96 hours) are yet unknown. It is hoped that clinicians will continue to encourage patients to participate in randomized clinical trials so that optimal therapy for early ovarian cancer can be established.

UR - http://www.scopus.com/inward/record.url?scp=0030101683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030101683&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 86

EP - 137

JO - Current Problems in Cancer

JF - Current Problems in Cancer

SN - 0147-0272

IS - 2

ER -